| Literature DB >> 29687465 |
Yoshihide Asano1, Masatoshi Jinnin2, Yasushi Kawaguchi3, Masataka Kuwana4, Daisuke Goto5, Shinichi Sato1, Kazuhiko Takehara6, Masaru Hatano7, Manabu Fujimoto8, Naoki Mugii9, Hironobu Ihn2.
Abstract
Several effective drugs have been identified for the treatment of systemic sclerosis (SSc). However, in advanced cases, not only their effectiveness is reduced but they may be also harmful due to their side-effects. Therefore, early diagnosis and early treatment is most important for the treatment of SSc. We established diagnostic criteria for SSc in 2003 and early diagnostic criteria for SSc in 2011, for the purpose of developing evaluation of each organ in SSc. Moreover, in November 2013, the American College of Rheumatology and the European Rheumatology Association jointly developed new diagnostic criteria for increasing their sensitivity and specificity, so we revised our diagnostic criteria and severity classification of SSc. Furthermore, we have revised the clinical guideline based on the newest evidence. In particular, the clinical guideline was established by clinical questions based on evidence-based medicine according to the New Minds Clinical Practice Guideline Creation Manual (version 1.0). We aimed to make the guideline easy to use and reliable based on the newest evidence, and to present guidance as specific as possible for various clinical problems in treatment of SSc.Entities:
Keywords: diagnostic criteria; guidelines; severity classification; systemic sclerosis; treatment
Mesh:
Substances:
Year: 2018 PMID: 29687465 DOI: 10.1111/1346-8138.14162
Source DB: PubMed Journal: J Dermatol ISSN: 0385-2407 Impact factor: 4.005